The United States is in the midst of a religious revolution. Or, perhaps it is better to say a non-religious revolution. Around a quarter of US adults now say they have no religion. The great majority of these religious “nones” also say that they used to belong to a religion but no longer do. These are the nonverts: think “converts,” but from having religion to having none. Even on the most conservative of estimates, there are currently about 59 million of them in the United States.

Nonverts: The Making of Ex-Christian America (Oxford UP, 2022) by Professor Stephen Bullivant explores who they are and why they joined the rising tide of the ex-religious. It draws on dozens of interviews, original analysis of high-quality survey data, and a wealth of cutting-edge studies to present an entertaining and insightful exploration of America’s ex-religious landscape. While American religion is not going to die out any time soon, ex-Christian America is a growing presence in national life. America’s religious revolution is not only a religious one—it is catalyzing a profound social, cultural, moral, and political transformation.

Stephen Bullivant is Professor of Theology and the Sociology of Religion at St Mary’s University, London. He is professorial research fellow at University Notre Dame in Sydney, Australia. He holds doctorates in Theology (from Oxford) and Sociology (from Warwick). He joined St Mary’s in 2009, having previously held posts at Heythrop College, London, and Wolfson College, Oxford. He’s also held Visiting fellowship at the Institute for Social Change at the University of Manchester, Blackfriars Hall at University of Oxford, and the Institute for Advanced Studies at the University College London.

Carrie Lynn Evans is a PhD student at Université Laval in Quebec City. carrie-lynn.evans@lit.ulaval.ca @carrielynnland

Learn more about your ad choices. Visit megaphone.fm/adchoices

Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/book-of-the-day

Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases